AFP and hepatocellular carcinoma: Although ramucirumab failed to meet its primary endpoint as second-line treatment in the REACH trial,117 subgroup analysis found survival benefit in patients with AFP of 400 ng/ml or higher.118–121 This was later confirmed in the REACH-2 trial,122 which led to the approval of ramucirumab as second-line treatment for advanced HCC.